Norihito Soga1, Takumi Kageyama1, Yuji Ogura1, Tomomi Yamada2, Norio Hayashi1. 1. Department of Urology, Aichi Cancer Center Hospital, Nagoya, Japan. 2. Department of Clinical Epidemiology and Biostatistics Graduate School of Medicine, Osaka University, Suita, Japan.
Abstract
INTRODUCTION: The efficacy of conversion from a luteinizing hormone-releasing hormone agonist to an antagonist was evaluated prospectively in patients with castration-resistant prostate cancer. MATERIALS AND METHODS: From October 2012 to December 2014, 8 cases with a serum testosterone level ≥ 20 ng/dl during following androgen deprivation therapy were enrolled and received degarelix monthly. The primary end-pointgoal was to determine the effective prostate-specific antigen response rate. The secondary end-pointgoal was to assess the proportion of cases with a decrease in serum testosterone level to < 20 ng/ml. RESULTS: One patient achieved a complete response, with a prostate-specific antigen level of 0.02 ng/ml at the nadirend of the study. The effective response rate was 25.0% (2/8), and the proportion of cases with prostate-specific antigen decline was 62.5% (5/8). In 5/8 cases (5/8, 62.5%), serum testosterone levels declined to < 20 ng/dl. CONCLUSION: Switching to a luteinizing hormone-releasing hormone antagonist in patients with testosterone levels ≥ 20 ng/dl may be an option in sequential androgen deprivation therapy for some patients.
INTRODUCTION: The efficacy of conversion from a luteinizing hormone-releasing hormone agonist to an antagonist was evaluated prospectively in patients with castration-resistant prostate cancer. MATERIALS AND METHODS: From October 2012 to December 2014, 8 cases with a serum testosterone level ≥ 20 ng/dl during following androgen deprivation therapy were enrolled and received degarelix monthly. The primary end-pointgoal was to determine the effective prostate-specific antigen response rate. The secondary end-pointgoal was to assess the proportion of cases with a decrease in serum testosterone level to < 20 ng/ml. RESULTS: One patient achieved a complete response, with a prostate-specific antigen level of 0.02 ng/ml at the nadirend of the study. The effective response rate was 25.0% (2/8), and the proportion of cases with prostate-specific antigen decline was 62.5% (5/8). In 5/8 cases (5/8, 62.5%), serum testosterone levels declined to < 20 ng/dl. CONCLUSION: Switching to a luteinizing hormone-releasing hormone antagonist in patients with testosterone levels ≥ 20 ng/dl may be an option in sequential androgen deprivation therapy for some patients.
Authors: N Mottet; J Bellmunt; M Bolla; S Joniau; M Mason; V Matveev; H P Schmid; T van der Kwast; T Wiegel; F Zattoni; A Heidenreich Journal: Actas Urol Esp Date: 2011-07-14 Impact factor: 0.994
Authors: Giuseppe Di Lorenzo; Carlo Buonerba; Riccardo Autorino; Sabino De Placido; Cora N Sternberg Journal: Drugs Date: 2010-05-28 Impact factor: 9.546
Authors: Yohann Loriot; Kurt Miller; Cora N Sternberg; Karim Fizazi; Johann S De Bono; Simon Chowdhury; Celestia S Higano; Sarah Noonberg; Stefan Holmstrom; Harry Mansbach; Frank G Perabo; De Phung; Cristina Ivanescu; Konstantina Skaltsa; Tomasz M Beer; Bertrand Tombal Journal: Lancet Oncol Date: 2015-04-14 Impact factor: 41.316
Authors: Alexandra Masson-Lecomte; Laurent Guy; Philippe Pedron; Franck Bruyere; Morgan Rouprêt; Bonaventure Nsabimbona; Mickael Dahan; Patrice Hoffman; Laurent Salomon; Dimitri Vordos; Andras Hoznek; Philippe Le Corvoisier; Pierrick Morel; Claude Abbou; Alexandre de la Taille Journal: World J Urol Date: 2012-04-15 Impact factor: 4.226
Authors: Laurence Klotz; Laurent Boccon-Gibod; Neal D Shore; Cal Andreou; Bo-Eric Persson; Per Cantor; Jens-Kristian Jensen; Tine Kold Olesen; Fritz H Schröder Journal: BJU Int Date: 2008-12 Impact factor: 5.588
Authors: Juan Morote; Anna Orsola; Jacques Planas; Enrique Trilla; Carles X Raventós; Lluís Cecchini; Roberto Catalán Journal: J Urol Date: 2007-08-14 Impact factor: 7.450
Authors: Laurence Klotz; Rodney H Breau; Loretta L Collins; Martin E Gleave; Tom Pickles; Frederic Pouliot; Fred Saad Journal: Can Urol Assoc J Date: 2017 Jan-Feb Impact factor: 1.862
Authors: E David Crawford; Axel Heidenreich; Nathan Lawrentschuk; Bertrand Tombal; Antonio C L Pompeo; Arturo Mendoza-Valdes; Kurt Miller; Frans M J Debruyne; Laurence Klotz Journal: Prostate Cancer Prostatic Dis Date: 2018-08-21 Impact factor: 5.554